Royalty Pharma plc (RPRX)
- Previous Close
27.89 - Open
27.85 - Bid 28.14 x 1000
- Ask 28.18 x 1000
- Day's Range
27.69 - 28.19 - 52 Week Range
25.92 - 36.48 - Volume
1,775,551 - Avg. Volume
2,724,383 - Market Cap (intraday)
16.824B - Beta (5Y Monthly) 0.45
- PE Ratio (TTM)
11.13 - EPS (TTM)
2.53 - Earnings Date May 9, 2024
- Forward Dividend & Yield 0.84 (3.01%)
- Ex-Dividend Date May 16, 2024
- 1y Target Est
45.50
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
www.royaltypharma.comRecent News: RPRX
Performance Overview: RPRX
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RPRX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RPRX
Valuation Measures
Market Cap
12.45B
Enterprise Value
17.36B
Trailing P/E
11.02
Forward P/E
8.20
PEG Ratio (5yr expected)
1.16
Price/Sales (ttm)
7.14
Price/Book (mrq)
1.91
Enterprise Value/Revenue
7.37
Enterprise Value/EBITDA
9.20
Financial Highlights
Profitability and Income Statement
Profit Margin
48.20%
Return on Assets (ttm)
5.62%
Return on Equity (ttm)
17.34%
Revenue (ttm)
2.35B
Net Income Avi to Common (ttm)
1.13B
Diluted EPS (ttm)
2.53
Balance Sheet and Cash Flow
Total Cash (mrq)
495.31M
Total Debt/Equity (mrq)
60.84%
Levered Free Cash Flow (ttm)
-1.25B
Research Analysis: RPRX
Analyst Price Targets
Fair Value
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Research Reports: RPRX
Mid Cap U.S. Pick List April 2024
This pick list highlights constituents of the Morningstar US Mid Cap Index that we believe offer investors the best risk-adjusted return prospects. The market capitalization range for U.S. mid-caps typically falls between $1 billion and $8 billion and represents 20% of the total capitalization of the U.S. equity market.
Mid Cap U.S. Pick List March 2024
This pick list highlights constituents of the Morningstar US Mid Cap Index that we believe offer investors the best risk-adjusted return prospects. The market capitalization range for U.S. mid-caps typically falls between $1 billion and $8 billion and represents 20% of the total capitalization of the U.S. equity market.
Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We Cover
In this edition, we explore oil and gas exploration and production opportunities; Ameriprise manages to get a fair value estimate raise; we launch coverage of Kongsberg Gruppen; and Royalty Pharma, Hanesbrands, and Orsted.
Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We Cover
In this edition, we explore oil and gas exploration and production opportunities; Ameriprise manages to get a fair value estimate raise; we launch coverage of Kongsberg Gruppen; and Royalty Pharma, Hanesbrands, and Orsted.